Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SVRA

+ Watchlist+ Portfolio

Savara, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$4.48
52-Week Range
$4.13 – $7.01
Market Cap
$1.04B
P/E (TTM)
—
EPS (TTM)
-0.60
Dividend Yield
0.00%
Advanced Metrics
Price/Book
11.13
PEG Ratio
—
Return on Equity
-151.05%
Return on Assets
-65.72%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
8.55
Debt/Equity
0.29
Total Debt
$31.57M
Free Cash Flow
$-73.67M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.17B

Market Snapshot

About

Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disorder. Savara is advancing novel therapies through clinical trials to address significant unmet medical needs.